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Clinical trials are essential to advancing knowledge to reduce disease morbidity and mortality; however,
ethnic and racial minorities remain under-represented in those studies. We explored knowledge and
perceptions of clinical trials among Mexican-Americans in Texas. We conducted focus groups (N ¼ 128)
stratiﬁed by gender, language preference, and geographical location. This paper presents four emergent,
primary themes: 1) knowledge and understanding of clinical trials, 2) fears and concerns about
participating, 3) perceived beneﬁts of participating, and 4) incentives to participate. Results suggest that
lack of knowledge and understanding of clinical trials leads to misunderstanding about research,
including fears and lack of trust. Participants indicated that fears related to perceived experimentation,
harm, immigration status, and lack of clinical trial opportunities within their communities were barriers
to participation. On the other hand, free healthcare access, helping family members in the future, and
monetary incentives could facilitate participation. We also found differences across themes by language,
gender, and place of residence. Findings from our study could inform the development of interventions
to enhance recruitment of Mexican-American participants into clinical trials.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinical trials tell researchers whether new therapies help or
hurt different population groups [1]. Despite the National Institutes
of Health’s efforts to increase the number of women and in-
dividuals from different racial and ethnic subgroups in all its fun-
ded clinical studies, minorities remain under-represented. It ishool of Public Health, Center
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nter, Department of Behavior
Inc. This is an open access article uestimated that only 1% of the 10,000 National Cancer Institute
(NCI)esponsored clinical trials have focused on racial and ethnic
minorities [2]. Hispanic accrual rates in nationwide cancer clinical
trials are 2e4% [3,4]. Such low rates are especially surprising in
Texas, where Hispanics represent about 40% of the population [5]
and are expected to be the majority by 2020 [6].
Researchers have explored barriers and facilitators to clinical
trial participation amongminority groups. Commonly, Hispanics do
not participate because they are unaware of trial opportunities, lack
transportation, mistrust research and the medical system, and have
other family considerations [7]. Focus groups with Mexican-
American, Medicaid-eligible patients found that although most
believe clinical trials help advance science, they cite a number of
participation barriers, including fear of adverse events, mistrust of
physicians, fear of experimentation led by inexperienced physi-
cians, language, and lack of time and transportation [8]. A study of
immigrant Latinos identiﬁed similar barriers including fear of
experimentation or harm, lack of transportation, time conﬂicts, and
language. They reported facilitators to participation that included
wanting to contribute to a disease cure, helping a close family
member with a disease, accessing healthcare, and working withnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Few qualitative studies have explored factors that inﬂuence
Hispanics’ participation in clinical trials [8e10]. Most of these
studies have been conducted among Spanish-speaking females
[8,9], or have made comparisons between Hispanics and African
Americans [9]. However, little is known about how perceptions of
clinical trials among Hispanics differ by gender, place of residence
in the U.S., or preferred language. To our knowledge, there is only
one comparative examination of factors inﬂuencing decisions to
participate in clinical trials among English and Spanish-speaking
individuals; yet, in that study, only four out of thirty English-
speaking participants self-identiﬁed as Hispanic, so authors could
not examine differences between English and Spanish-speaking
Hispanics [10].
Our study was part of cancer control research activities con-
ducted by an NCI-funded Community Network Program Center and
the Center for Clinical and Translational Science Community
Engagement Component. These projects aim to decrease the
burden of cancer in Houston, Brownsville, and El Paso, Texas. Self-
identiﬁed Hispanics largely comprise these three communities.
Houston is a large, metropolitan city in southeast Texas, and
Brownsville and El Paso are smaller cities that share a border with
Mexico. Between 34% [11] and 86% [12] of household residents in
these communities report Spanish as the primary language spoken
at home. It is estimated that Mexican Americans make up 32% of
the foreign-born population in the US [13]. The foreign-born pop-
ulation in Houston, El Paso, and Brownsville are estimated at 25.3%,
25.9% and 24.7%, respectively [5]. However, despite being the
largest Hispanic subgroup in the country, our understanding about
Mexican American perceptions of clinical trial participation is
limited. Thus, in this study, we wanted to better understand the
reasons for the low rates of clinical trial participation in these
communities, and explore Mexican-Americans’ knowledge and
perceptions of clinical trials.
2. Methods
Two bilingual members of the research team conducted focus
groups between 2012 and 2013 using a semi-structured interview
guide (Table 1). The research team developed the guide in English
based on a review of related studies and discussions with the full
research team. Bilingual study staff translated the guide into
Spanish. Using a convenience sampling method, research staff
invited English- or Spanish-speaking Hispanic adults to participate.
They recruited participants using ﬂyers and one-on-one contact at
community-based organizations and public housing complexes.
Focus groups were stratiﬁed by gender, preferred spoken language
(English or Spanish), and place of residence (Houston, Brownsville,
or El Paso). The Institutional Review Board of the University of
Texas Health Science Center at Houston approved the study
protocol.
2.1. Data collection
Bilingual, trainedmoderators led the focus groups, accompanied
by one note taker at each location. Moderators conducted all focus
groups at locations that included community centers and apart-
ment complexes. Participants reviewed and signed an informed
consent and, subsequently, completed a brief demographic survey
that inquired about participants’ age, marital status, country of
origin, years living in the U.S., education, household income, and
medical insurance status. Moderators audio-recorded all focus
groups; each lasted 60e90 min. As shown in Table 1, at the
beginning of all focus groups, moderators assessed participants’
prior knowledge of clinical trials, and then read aloud a briefdeﬁnition of clinical trials to participants. At the end of each focus
group, each participant received a $20 gift card.
2.2. Data analysis
The coding and analysis team were bilingual. The coding team
consisted of four research coordinators, and the analysis team
included members of the research team who summarized and
interpreted the data. We analyzed participant demographic infor-
mation data using SPSS v. 21 software (IBM-SPSS, Inc.). We tran-
scribed all focus group recordings verbatim, in the language in
which they were conducted, and then reviewed them for accuracy.
Next, the coding team conducted the data analysis using Atlas.ti,
version 7. Three coders read all transcripts, taking notes on major
themes and common threads and ideas. Then, they developed an
initial draft of the coding scheme, subsequently revised and ﬁnal-
ized it based on group consensus.
The coding team used the co-occurrence explorer tool in Atlas.ti
to determine how codes were related and then they began linking
codes to form a thematic network. The coders discussed the
network, that is, all codes nested under larger themes, with the full
research team. The research team reviewed all themes and the
associated quotations for the codes in that theme. After the dis-
cussion, the team revised the network based on ﬁndings from this
review. The research team used the completed network and
accompanying data to guide the development of this manuscript.
We conducted the analyses using the systematic and iterative
process described above. While we had not intended to formally
analyze group differences, as the analytic process proceeded these
differences began to emerge. Thus, we used a thematic analysis
technique to compare the emergent themes by gender, language,
and place of residence by creating document families in Atlas.ti.
Then, a staff member used these families to extract queries of all
codes associated with the primary themes and reviewed them to
identify similarities and differences across them.
3. Results
3.1. Participant demographics
We conducted 15 focus groups, 8 with females and 7withmales.
We held 4 focus groups in Brownsville, 7 in El Paso, and 4 in
Houston. We conducted 8 groups in Spanish and 7 in English
(Table 2). A total of 128 adults took part in the study, including 54
males and 72 females (see Table 3). The majority of participants
were Spanish speakers (63.3%), born in Mexico (60.9%), had earned
a high school degree or less (63.4%), had a household income of less
than $30,000 (67.2%), andwere uninsured (66.4%). About half of the
participants weremarried (47.7%). On average, participants were 40
years old and had lived in the U.S. for 23 years.
3.2. Qualitative themes
Results are organized into four emerging themes: 1) knowledge
and understanding of clinical trials, 2) fears and concerns, 3)
perceived beneﬁts of participation, and 4) incentives to participate.
Findings presented below are given ﬁrst as similarities across all
focus groups and then as differences by gender, language, and place
of residence.
3.3. Knowledge and understanding of clinical trials
Overall, participants’ knowledge about clinical trials was
limited. They commonly associated clinical trials with various types
of research, from therapeutic or drug trials to marketing research
Table 1
Focus group guide.
1. What do you know about clinical trials?a
2. Have you or anyone you know ever participated in a clinical trial?
3. Has anyone ever invited you to participate in any clinical trial?
4. Have you ever seen or heard about a speciﬁc clinical trial?
5. How do you feel about people participating in clinical trials? And why?
6. Do you think you would be willing to participate in a clinical trial? Why or why not?
7. What things concern or worry you about participating in clinical trials?
8. What would make it difﬁcult for you to participate in a clinical trial?
9. What would make you more willing to participate in a clinical trial?
10. Do you think clinical trials are important for you or your family? Why or why not?
11. If you have children, would you enroll them in a clinical trial? Why or why not?
12. What would be some good things about being in a clinical trial – for you, your family, or your community?
13. How do you think others in your community feel about clinical trials?
14. What type of research do you think is needed in your community?
15. Is there anything we didn’t discuss about clinical trials that you would like to tell us or think we should know?
a After this question the following deﬁnition was read aloud to participants: Clinical trials are used to ﬁnd out if something newworks, like a newmedicine. Clinical trials are
research studies that people participate in to help doctors ﬁnd ways to improve health and care for diseases. In clinical trials, some people get one treatment and some people
get a different or no treatment so that doctors can compare and see if one treatment works better than another one.
Table 2
Number of focus groups conducted by location, language, and gender.
English Spanish
Male Female Male Female
Houston 1 1 1 1
Brownsville 1 1 1 1
El Paso 2 1 2 2
Table 3
Participant demographics by focus group location.
Brownsville
No. of focus groups 4
No. of Participants 35
Preferred language
English (%) 14 (40.0)
Spanish (%) 21 (60.0)
Gender
Male (%) 13 (37.1)
Female (%) 22 (62.9)
Missing (%) 0 (0.0)
Age
Avg. age (SD) 42 (12)
Partner status
Single/never married (%) 5 (14.3)
Married (%) 25 (71.4)
Origin
Mexican (%) 33 (94.3)
Other (%) 2 (5.7)
Nativity status
USA (%) 14 (40.0)
Mexico (%) 20 (57.1)
Years living in the U.S.
Average 24
Education
Less than high school (%) 15 (42.8)
High school or vocational school (%) 12 (34.4)
College/Graduate/professional school (%) 8 (22.8)
Household income
$0e$9,999 (%) 7 (20.0)
$10,000e$19,999 (%) 18 (51.5)
Medical insurance
No medical insurance (%) 17 (48.6)
Medicaid (%) 0 (0.0)
Medicare (%) 1 (2.9)
Private or managed care (%) 15 (42.9)
Participation in clinical trial?
Yes (%) 7 (20.0)
No (%) 28 (80.0)
Don’t know or missing (%) 0 (0.0)
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doctor and the doctor sends you to get labs. Those are clinical trials.”
(El Paso, female, Spanish). Also, some participants thought that
clinical trials are conducted at health departments, in laboratories,
or in hospitals by lab technicians, radiologists, or doctors. None of
the participants said that researchers (medical or non-medical)
conducted clinical trials. At the beginning of each focus group,
the moderators provided a deﬁnition of clinical trials (Table 1), yetEl Paso Houston Total
7 4 15
66 27 128
18 (27.3) 15 (55.6) 47 (36.7)
48 (72.7) 12 (44.4) 81 (63.3)
27 (40.9) 14 (51.9) 54 (42.2)
39 (59.1) 11 (40.7) 72 (56.3)
0 (0.0) 2 (7.4) 2 (1.5)
44 (16) 30 (12) 40 (15)
23 (34.8) 19 (70.4) 47 (36.7)
31 (47.0) 5 (18.5) 61 (47.7)
66 (100.0) 27 (100.0) 126 (98.4)
0 (0.0) 0 (0.0) 2 (1.6)
20 (30.3) 14 (51.9) 48 (37.5)
45 (68.2) 13 (48.1) 78 (60.9)
22 22 23
31 (47.0) 7 (25.9) 53 (41.5)
25 (37.8) 3 (11.2) 40 (31.3)
10 (15.2) 17 (62.9) 34 (26.8)
35 (53.0) 10 (37.0) 52 (40.6)
7 (10.6) 9 (33.3) 34 (26.6)
48 (72.7) 20 (74.1) 85 (66.4)
7 (10.6) 3 (11.1) 10 (7.8)
6 (9.1) 0 (0.0) 7 (5.5)
3 (4.5) 1 (3.7) 19 (14.8)
8 (12.1) 0 (0.0) 15 (11.7)
54 (81.8) 21 (77.8) 103 (80.5)
4 (6.1) 6 (22.2) 10 (7.8)
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their experiences when seeking medical care.
Across all groups, participants frequently mentioned the need
for more information about clinical trials. Many indicated that
having sufﬁcient information about what is involved in the study,
the disease being investigated, medications, risks, side effects, and
costs related to participation would make them more likely to
consider participating. They also believed that having bilingual
recruiters and staff could help enrollment efforts and that infor-
mation provided should use simple terminology in Spanish. One
participant said, “… [language] is important … often times we are
afraid because we don’t have information … it’s important that they
speak Spanish [and] that they don’t use those medical terms.” (El Paso,
Male, Spanish). There was consensus across all focus groups that
the community needs more information and education about
clinical trials and that bilingual communication using appropriate
literacy levels could help community involvement. One participant
said, “… a lot of people are ignorant about what a clinical trial is. So,
yeah, education. Educate us about that topic” (El Paso, Female,
English).
3.3.1. Differences by language
Our results indicated a greater lack of understanding about the
meaning of clinical trials and what it entails among mono-lingual
Spanish speakers. One participant said, “Being bilingual helps a lot
because, you see, many times there are words in English that I don’t
even understand. I didn’t go to school to learn English, so if you are
bilingual you would know it.” (El Paso, Male, Spanish). English-
speaking participants had a slightly better concept of clinical tri-
als, their comments showed fewer misunderstandings, and the
conversations quickly moved on to discussions about information
they needed to consider for participation.
3.3.2. Differences by geographical location
Participants from Brownsville and El Paso indicated not being
aware of research opportunities in their communities and that they
had not been approached to participate in clinical trials. A partici-
pant in Brownsville said, “There are many projects here, and we don’t
know about them because we are not given information about them
…” (Female, Spanish). Participants believed that the lack of infor-
mation, limited understanding of clinical trials, and little exposure
to clinical trial opportunities are barriers to participation.
3.3.3. Differences by gender
We found no major differences in knowledge and understand-
ing of clinical trials by gender. Both males and females indicated
similar awareness, and both expressed the need for more infor-
mation. Males were more speciﬁc as to what type of information
they needed in order to make a decision to participate in a clinical
trial (e.g., purpose of the study, what medications are involved, side
effects, and other risks), compared with females.
3.4. Fear and concerns about participating in clinical trials
Many focus group participants expressed fears and concerns
about clinical trials. Across all groups, they seemed generally con-
cerned about being “used” in experiments, feeling like a guinea pig.
One participant said, “I probably wouldn’t do it because I would feel
like I’m a guinea pig, and I’m taking some medicine that I don’t even
know.” (Houston, Male, English). Fears of experimentation were
associated with distrust of research, as several participants
expressed concerns about being “infected with a disease,” “injected
with a virus,” or “diagnosed with something I don’t have.”
Participants in all focus groups also expressed concerns about
side effects and medication safety. Many said they would not agreeto take newmedications due to potential negative side effects. Also,
early phase trials were perceived as more risky or dangerous, and
some participants indicated that they would rather wait until any
medications being tested were safer. One participant stated, “I’m
thinking I wouldn’t be a guinea pig for them. I mean, I would rather
play it safe. If someday they tell me it is going to help me out and at the
end it does not help me, and it just leaves me the same or worse. So
why take the risk?” (El Paso, Male, English).
All participants expressed concerns about adverse effects
related to their participation. Most said they would not participate
in a clinical trial that could potentially harm or cause them pain.
Some participants also feared needle sticks and having blood
drawn. Participants seemed more receptive to participating in
studies of less-invasive procedures or those less likely to cause
them bodily harm. Importantly, participants in all focus groups
discussed fears related to immigration status. In fact, participants
said that fears of being found out and deported might decrease the
likelihood of participation among undocumented immigrants.
3.4.1. Differences by geographical location
Participants from Houston and Brownsville thought that fears
about participation in clinical trials were due to lack of awareness
and information in their communities. Participants from El Paso
expressed concerns about physical harm caused by medications
and many expressed hesitancy to take medications as part of their
participation.
3.4.2. Differences by gender
Both males and females mentioned concerns about risks and
side effects. However, males expressed concerns about the poten-
tial of being physically harmed (e.g., developing a tumor or organ
damage) more often than fear of pain. One participant indicated
that he would rather give blood than take a medication that could
cause him harmful side effects. Females, on the other hand,
expressed concerns about experiencing pain as a result of their
participation more often than concerns about physical harm. For
both genders, concerns of physical harm or pain were deterrents of
participation.
3.4.3. Differences by language
We found no differences in fears and concerns related to lan-
guage spoken.
3.5. Perceived beneﬁts of participating in clinical trials
Across all focus groups, participants indicated that they would
be willing to participate in clinical trials to help advance science
and to beneﬁt society. One participant said, “I think that clinical
studies are very good and can help out our friends, family, and people
we care about. And, even if we don’t know somebody, we should care
about them.” (Houston, Male, English). Participants also mentioned
the potential of helping their families and helping future genera-
tions as a positive outcome of clinical trial participation. One
participant said, “I would let others test me in case they ﬁnd a cure
and my family could beneﬁt from it.” (Brownsville, Female, Spanish).
Others said that improving their own health status would be a
compelling reason to participate. An important perceived beneﬁt
across groups included hopes of improving their poor health status
by getting access to health care or receiving medications. Many
participants said they would only consider participating in a trial as
a last resort, if they were terminally ill or had a serious condition.
Lastly, some thought that people in good health should not take
part in therapeutic clinical trials because it could be detrimental to
their health, and it would not contribute to science. For example,
one participant said, “It’s worth it for those with a health problem, but
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English).3.5.1. Differences by geographic location
For participants from El Paso, the perception that participation
could lead to the discovery of new diseases and treatments and
helping to ﬁnd a cure for diseases were salient themes. In contrast,
only one participant from Brownsville said that she would partic-
ipate to help ﬁnd a cure, while no participants from Houston
brought up this point. Participants in El Paso also expressed a sense
of cohesion and a desire to give something back to their commu-
nity. One participant said, “We,Hispanics, need to get involved to help
each other out because we are a minority.” (Male, Spanish).3.5.2. Differences by gender
Female participants indicated altruistic motives for participating
in a clinical trial (e.g., desire to help future generations). Males
indicated more frequently that they would participate to beneﬁt
their own poor health than a desire to help others. Both males and
females expressed a desire to participate in clinical trials to help
advance science. However, when verbalizing their willingness to
help, females indicated speciﬁc examples of how their participation
in clinical trials could help advance science, which included dis-
covery of new diseases and development of treatments and med-
ications. Comments made by males were more general. For
example, one male said, “[Participating] more than anything is for a
good cause. To help somebody, to save somebody, to improve some-
thing.” (Brownsville, Male, Spanish).3.5.3. Differences by language
Participants in the Spanish-speaking groups mentioned the
desire to help future generations more often than English-speakers
did. We observed no other differences by language spoken.3.6. Incentives to participation
Across all groups, incentives ranged from ﬁnancial incentives to
decreasing logistic barriers. Participants believed that monetary
incentives, such as gift cards or cash stipends, could encourage
participation. Across all groups, participants mentioned having
access to medications and the potential to offset costs associated
withmedical procedures as incentives. Other incentives mentioned
were providing transportation to and from the study sites,
compensating mileage, and providing refreshments.
Many indicated that they would want to participate in a clinical
trial to learn more about their own health status or to ﬁnd out if
they had a disease. Others believed that they would be able to get
free check-ups, receive blood work results, or gain access to their
medical information by participating in a trial. Because some
believed that participation would facilitate medical screenings or
tests, participants discussed expectations about ﬁnding out test
results as incentives to participation. One woman stated, “I think
people want to take advantage of the labs since they will not charge
you for them.” (Brownsville, Female, Spanish).3.6.1. Differences by geographic location
Participants from Brownsville believed that the uninsured
would beneﬁt from participation by obtaining free access to
healthcare. For participants from El Paso, a major incentive to
participate was getting free check-ups, and access to medications.
Some participants from El Paso believed that they had to pay for
medications and other health care, and some said that they would
not participate in a clinical trial for this reason.3.6.2. Differences by gender or language
We found no differences in perceived incentives to participation
by either language spoken or gender.
4. Discussion
The purpose of the study was to explore knowledge and per-
ceptions about clinical trials among Mexican Americans residing in
three cities in Texas. We aimed to identify barriers and facilitators
that would help improve their participation in this type of research.
By capitalizing on unique data containing perceptions of English-
and Spanish-speaking Mexican American adults living in one large
metropolitan city and two U.S.-Mexico border cities in Texas, we
were able to examine differences by gender, language of preference,
and geographical location. To our knowledge, this is the ﬁrst study
that qualitatively examined similarities and differences in knowl-
edge and perceptions of clinical trials amongMexican Americans in
Texas.
Our ﬁndings are consistent with previous qualitative research
exploring barriers and facilitators of clinical trial participation
among Hispanics. First, we found limited knowledge and under-
standing among our focus group participants. Among Spanish
speakers, the term estudios clínicos (clinical trials) was confusing
and hard to understand. This is consistent with ﬁndings from a
study of Spanish-speaking Puerto Ricans [14]. Another study found
that Hispanic participants were familiar with the term experimental
studies andwere able to deﬁne the term in their ownwords but that
they were less familiar with the term clinical trials [15]. However, it
is unclear whether using other terms (e.g., experimental studies)
could exacerbate fears of experimentation. Future studies should
assess participant’s acceptability and comprehension of alternative
Spanish-language terms.
Our ﬁndings related to fears and concerns about clinical trial
participation are similar to those found in other studies, such as
fears of experimentation, concerns about unethical research prac-
tices, and fears of potential harm [8,9]. However, we observed that
males and females articulated their concerns differently about
potential harm and pain related to participation. Females were
more concerned about pain than males, while males more often
expressed concerns about physical harm than females did. The way
participants voiced their fears and concerns about participation
might be relevant to researchers who are developing targeted
clinical trial educational messages to Mexican-Americans. Future
research should examine whether these ﬁndings are genuinely
gender-based concerns and ways that they could be addressed.
In all three cities, we found that participants’ fears of deporta-
tion could be a barrier to their participation. This is of particular
importance among immigrant communities, as those included in
our study. Mexican Americans are the largest ethnic group of un-
documented migrants in the US; of the 10.3 million estimated
undocumented migrants, Mexican Americans make up 57%, and
14% of those reside in Texas [13]. Although ﬁndings related to fears
and concerns about participation in clinical trials are not neces-
sarily unique to Mexican Americans, other groups have also
expressed similar concerns [8,9]. Nevertheless, there may be dif-
ferences in the degree towhich these beliefs inﬂuence participation
particularly when logistic, economic and other concerns such as
those related to immigrant status are considered.
Focus group participants expressed receptivity to participate in
clinical trials and a desire to help research and science, which is
consistent with another study among Mexican Americans [8].
Participants thought that taking part in a clinical trial would give
them access to healthcare, a phenomenon known as therapeutic
misconception [16], and has been observed and studied in other
ethnic populations [17]. We found that major incentives to
M. Arevalo et al. / Contemporary Clinical Trials Communications 4 (2016) 52e57 57participation were monetary stipends and eliminating logistic
barriers. Although these incentives are not unique to Mexican-
Americans in Texas, we believe that is important to highlight
ﬁndings that are similar to those of other qualitative studies [18].
We also found that females expressed more altruistic motives for
participation such as the desire to help others, whereas males said
they would participate in a clinical trial to beneﬁt their own health.
We believe that this might be related to gender roles and expec-
tations, whereby Mexican American women are often expected to
take the role of caretakers and demonstrate collectivistic charac-
teristics [19]. Future studies should examine whether these ﬁnd-
ings are truly related to gender roles and expectations. Lastly, our
participants expressed an increased need for bilingual staff, use of
simple language in written materials, and the use of community
channels (e.g., media ads, word-of-mouth) to disseminate
information.
By examining our data across geographic regions, we were able
to gather information about our participants’ context and social
realities. Our ﬁndings suggest that participants in the border-town
communities, as compared to those in the metropolitan city, may
have less exposure to research and clinical trials information and
opportunities to participate. This lack of exposure may also
contribute to their fears and concerns about participation. A recent
review [20] reported that familiarity and interest in research
facilitated clinical trial participation. Thus, our ﬁndings identify an
opportunity to increase familiarity and access to research in these
geographic regions. We also found that altruistic motives were
more salient in border towns as compared to Houston. We believe
that this may be related to social cohesion within those commu-
nities and cultural aspects such as the desire to help others within
their communities.
Limitations of this study are related to its qualitative nature. One
limitation is that we used a convenience sample; hence, our ﬁnd-
ings are not generalizable to all Mexican-Americans or to a broader
Hispanic population. Future studies should explore participants’
perceptions of other Hispanic subgroups. A second limitation is that
other factors, such as education, ﬁnancial status, and other socio-
demographics may have inﬂuenced participants’ opinions; there-
fore, ﬁndings should not be attributed solely to cultural factors
since they may have also been inﬂuenced by socio-demographic
factors. Our study was not designed to tease apart potential dif-
ferences and we recommend future research in this area. We
acknowledge that some of our participants’ lacked sufﬁcient
knowledge of clinical trials and that this may have inﬂuenced their
perspectives, as well. Approximately 12% of participants indicated
having participated in a clinical trial on their demographic surveys.
However, this question was asked before participants were pro-
vided with a deﬁnition of clinical trials and before they discussed it
with other focus group participants; thus, we believe that 12%
participation might be an overestimation and it may be indicative
of their lack of sufﬁcient knowledge about the concept of clinical
trials. This was an important ﬁnding in our study and has impli-
cations for future research and development of educational mate-
rials to increase participation. Our last study limitation is that our
data did not permit comparisons in responses between those who
may and may not have participated in clinical trials because indi-
vidual survey responses could not be linked to comments made by
individuals during the focus group discussions.
A major strength of this study is its use of focus group meth-
odology. It allowed us to garner community perspectives on clinical
trial participation among Mexican-Americans, the largest under-
served minority group in the country. We thereby gained a better
understanding of barriers and facilitators to clinical trial partici-
pation through comparisons across gender, language, and place of
residence. These ﬁndings could inform the development ofinterventions to enhance recruitment of Mexican-American par-
ticipants into clinical trials.
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